London-based Cell Medica Ltd has raised £50 million from institutional investors to support development of its lead oncology product, CMD-003, for the treatment of patients with advanced lymphomas associated with the Epstein Barr virus. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
